Replimune Group, Inc. (REPL) Stock Analysis — Probabli.AI
AI-powered analysis for REPL (Replimune Group, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. AI consensus: Neutral.
Last price: $11.47 · Market cap: $972.0M · AI consensus: Neutral
Replimune Group, Inc., currently priced at $11.47, is showing promising developments in its oncolytic virus therapy pipeline, supported by positive trial results and significant funding. However, regulatory challenges and cautious analyst sentiment present headwinds. The stock's one-year outlook is moderately cautious, given current assessments, but there are substantial long-term growth…
Probabilistic 1-Year Outlook
- Bull 2000% · Neutral 5000% · Bear 3000%
- Replimune's recent positive headlines surrounding its pipeline and funding provide optimism. However, the analyst consensus and price targets suggest caution. The regulatory setback reported is a potential downside…
5-Year Outlook
- Bull 3500% · Neutral 4000% · Bear 2500%
SWOT Highlights
- Strength: Promising pipeline in oncolytic virus therapy
- Strength: Recent positive trial results
- Risk: Regulatory setbacks
- Risk: Current negative EPS surprise history
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
8 Wall Street analysts rate REPL a HOLD with a mean price target of $9.6.
Analysis generated Jul 6, 2026 · Model: gpt-4o. Run a fresh analysis on probabli.xyz/stock/REPL.
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.